Phenocopy and Phenoconversion: Do they Complicate Association Studies?

• Brockmöller J , KirchheinerJ, MeiselC, RootsI. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics1(2) , 125–151 (2000).
   PubMedGoogle Scholar
• Kirchheiner J , BertilssonL, BruusH, WolffA, RootsI, BauerM. Individualized medicine – implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry36(Suppl. 3) , S235–S243 (2003).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J , NickchenK, BauerM et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9(5) , 442–473 (2004).
   PubMed Web of Science ®Google Scholar
• Br⊘sen K , GramLF, HaghfeltT, BertilssonL. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol. Toxicol.60(4) , 312–314 (1987).
   PubMedGoogle Scholar
• Ayesh R , DawlingS, HaylerA et al. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers. Chirality 3(1) , 14–18 (1991).
   PubMed Web of Science ®Google Scholar
• Vormfelde SV , BrockmöllerJ, BauerS et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin. Pharmacol. Ther. 86(1) , 54–61 (2009).
   PubMed Web of Science ®Google Scholar
• O‘Neil WM , GilfixBM, MarkoglouN, Di Girolamo A, Tsoukas CM, Wainer IW. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur. J. Clin. Pharmacol.56(3) , 231–240 (2000).
   PubMed Web of Science ®Google Scholar
• Mitchell SC , ShahRR, ClementsDG, SmithRL. Changes in debrisoquine hydroxylation capacity following liver surgery. Hum. Exp. Toxicol.13(8) , 537–541 (1994).
   PubMed Web of Science ®Google Scholar
• Monek O , PaintaudG, BechtelY, MiguetJP, MantionG, BechtelPR. Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: a study of mutations CYP2D6*3 and CYP2D6*4. Eur. J. Clin. Pharmacol.54(1) , 47–52 (1998).
   PubMed Web of Science ®Google Scholar
• Amchin J , EreshefskyL, ZarycranskiW, TaylorK, AlbanoD, KlockowskiPM. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J. Clin. Pharmacol.41(4) , 443–451 (2001).
   PubMed Web of Science ®Google Scholar
• Nakashima D , TakamaH, OgasawaraY et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J. Clin. Pharmacol. 47(10) , 1311–1319 (2007).
   PubMed Web of Science ®Google Scholar
• Güzey C , NorströmA, SpigsetO. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther. Drug Monit.24(3) , 436–437 (2002).
   PubMed Web of Science ®Google Scholar
• Shiran MR , ChowdryJ, Rostami-HodjeganA et al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br. J. Clin. Pharmacol. 56(2) , 220–224 (2003).
   PubMed Web of Science ®Google Scholar
• Ieiri I , YamadaS, SetoK et al. A CYP2D6 phenotype–genotype mismatch in Japanese psychiatric patients. Pharmacopsychiatry 36(5) , 192–196 (2003).
   PubMed Web of Science ®Google Scholar
• Zourková A , HadasováE. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects. Gen. Physiol. Biophys.22(1) , 103–113 (2003).
   PubMed Web of Science ®Google Scholar
• Laine K , TybringG, HärtterS et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin. Pharmacol. Ther. 70(4) , 327–335 (2001).
   PubMed Web of Science ®Google Scholar
• Dalén P , DahlM, AnderssonK, BertilssonL. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br. J. Clin. Pharmacol.49(2) , 180–184 (2000).
   PubMed Web of Science ®Google Scholar
• Caraco Y , ShellerJ, WoodAJ. Impact of ethnic origin and quinidine coadministration on codeine‘s disposition and pharmacodynamic effects. J. Pharmacol. Exp. Ther.290(1) , 413–422 (1999).
   PubMed Web of Science ®Google Scholar
• Ito K , BrownHS, HoustonJB. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. Br. J. Clin. Pharmacol.57(4) , 473–486 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch T , PriceA. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician76(3) , 391–396 (2007).
   PubMed Web of Science ®Google Scholar
• Kiyotani K , MushirodaT, HosonoN et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics 20(9) , 565–568 (2010).
   PubMed Web of Science ®Google Scholar
• Kelly CM , JuurlinkDN, GomesT et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340 , C693 (2010).
   PubMed Web of Science ®Google Scholar
• Kreutz RP , StanekEJ, AubertR et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study. Pharmacotherapy 30(8) , 787–796 (2010).
   PubMed Web of Science ®Google Scholar
• Klein TE , AltmanRB, ErikssonN et al.; for International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J Med.360(8) , 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• Lockhart P , GuthrieB. Trends in primary care antidepressant prescribing 1995–2007: a longitudinal population database analysis. Br. J. Gen. Pract.61(590) , E565–E572 (2011).
   PubMed Web of Science ®Google Scholar
• Preskorn SH , ShahR, NeffM, GolbeckAL, ChoiJ. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J. Psychiatr. Pract.13(1) , 5–12 (2007).
   PubMedGoogle Scholar

▪ Website

• P450 Drug Interaction Table. Division of Clinical Pharmacology, Indiana University. http://medicine.iupui.edu/clinpharm/DDIs/table.aspx (Accessed 22April2012).
   Google Scholar